BRPI1014459A2 - derivados de 3-(1,2,3-triazol-4-il)pirrolo[2,3-b]-piridina" - Google Patents

derivados de 3-(1,2,3-triazol-4-il)pirrolo[2,3-b]-piridina"

Info

Publication number
BRPI1014459A2
BRPI1014459A2 BRPI1014459A BRPI1014459A BRPI1014459A2 BR PI1014459 A2 BRPI1014459 A2 BR PI1014459A2 BR PI1014459 A BRPI1014459 A BR PI1014459A BR PI1014459 A BRPI1014459 A BR PI1014459A BR PI1014459 A2 BRPI1014459 A2 BR PI1014459A2
Authority
BR
Brazil
Prior art keywords
pyrrolo
triazol
pyridine derivatives
pyridine
derivatives
Prior art date
Application number
BRPI1014459A
Other languages
English (en)
Inventor
Dieter Dorsch
Eugen Merkul
Margarita Wucherer-Plietker
Thomas J J Mueller
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of BRPI1014459A2 publication Critical patent/BRPI1014459A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
BRPI1014459A 2009-05-05 2010-04-08 derivados de 3-(1,2,3-triazol-4-il)pirrolo[2,3-b]-piridina" BRPI1014459A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102009019962A DE102009019962A1 (de) 2009-05-05 2009-05-05 3-([1,2,3]Triazol-4-yl)-pyrrolo[2,3-b]pyridinderivate
PCT/EP2010/002207 WO2010127754A1 (de) 2009-05-05 2010-04-08 3-([1,2,3]triazol-4-yl)-pyrrolo[2,3-b]pyridinderivate

Publications (1)

Publication Number Publication Date
BRPI1014459A2 true BRPI1014459A2 (pt) 2016-04-05

Family

ID=42315620

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1014459A BRPI1014459A2 (pt) 2009-05-05 2010-04-08 derivados de 3-(1,2,3-triazol-4-il)pirrolo[2,3-b]-piridina"

Country Status (17)

Country Link
US (1) US8541584B2 (pt)
EP (1) EP2427461B1 (pt)
JP (1) JP5731481B2 (pt)
KR (1) KR20120014183A (pt)
CN (1) CN102414211B (pt)
AR (1) AR076750A1 (pt)
AU (1) AU2010244772B2 (pt)
BR (1) BRPI1014459A2 (pt)
CA (1) CA2760844C (pt)
DE (1) DE102009019962A1 (pt)
EA (1) EA201101585A1 (pt)
ES (1) ES2436445T3 (pt)
IL (1) IL215725A (pt)
MX (1) MX2011011488A (pt)
SG (1) SG175245A1 (pt)
WO (1) WO2010127754A1 (pt)
ZA (1) ZA201108885B (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102010049877A1 (de) * 2010-11-01 2012-05-03 Merck Patent Gmbh 7-((1,2,3)Triazol-4-yl)-pyrrolo(2,3) pyrazinderivate
DE102010053347A1 (de) * 2010-12-03 2012-06-06 Merck Patent Gmbh 3-Hetaryl-substituierte Pyrrolo[2,3-b] pyridin-derivative als PDK1-Inhibitoren
DE102011008352A1 (de) * 2011-01-12 2012-07-12 Merck Patent Gmbh 5-([1,2,3]Triazol-4-yl)-7H-pyrrolo-[2,3-d]pyrimidinderivate
DE102011009961A1 (de) * 2011-02-01 2012-08-02 Merck Patent Gmbh 7-Azaindolderivate
DE102011105469A1 (de) * 2011-06-24 2012-12-27 Merck Patent Gmbh 7-Azaindolderivate
GB201114051D0 (en) 2011-08-15 2011-09-28 Domainex Ltd Compounds and their uses
NZ702571A (en) 2012-06-29 2017-02-24 Pfizer 4-(substituted-amino)-7h-pyrrolo[2,3-d]pyrimidines as lrrk2 inhibitors
JP6487921B2 (ja) 2013-12-17 2019-03-20 ファイザー・インク ＬＲＲＫ２阻害薬としての新規の３，４−二置換−１Ｈ−ピロロ［２，３−ｂ］ピリジンおよび４，５−二置換−７Ｈ−ピロロ［２，３−ｃ］ピリダジン
TW201613916A (en) 2014-06-03 2016-04-16 Gilead Sciences Inc TANK-binding kinase inhibitor compounds
SG11201702108PA (en) 2014-09-16 2017-04-27 Celgene Quanticel Res Inc Histone demethylase inhibitors
US9896436B2 (en) 2014-09-16 2018-02-20 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
ES2881195T3 (es) 2014-09-26 2021-11-29 Gilead Sciences Inc Derivados de aminotriazina útiles como compuestos inhibidores de quinasas que se unen a TANK
WO2017015152A1 (en) 2015-07-17 2017-01-26 Memorial Sloan-Kettering Cancer Center Combination therapy using pdk1 and pi3k inhibitors
CN108137586B (zh) 2015-09-14 2021-04-13 辉瑞大药厂 作为LRRK2抑制剂的新颖咪唑并[4,5-c]喹啉和咪唑并[4,5-c][1,5]萘啶衍生物
CN108430993A (zh) 2015-12-17 2018-08-21 吉利德科学公司 Tank-结合激酶抑制剂化合物
US10894784B2 (en) 2015-12-18 2021-01-19 Bayer Pharma Aktiengesellschaft Heteroarylbenzimidazole compounds
WO2017207534A1 (en) 2016-06-03 2017-12-07 Bayer Pharma Aktiengesellschaft Substituted heteroarylbenzimidazole compounds
CN115322192B (zh) * 2022-08-15 2023-07-14 重庆文理学院 吡咯并[3,4-b]吡啶类衍生物及其合成方法与应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747469A (en) 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
GB9904387D0 (en) 1999-02-25 1999-04-21 Pharmacia & Upjohn Spa Antitumour synergistic composition
GB0405055D0 (en) * 2004-03-05 2004-04-07 Eisai London Res Lab Ltd JNK inhibitors
JP2007533753A (ja) * 2004-04-23 2007-11-22 タケダ サン ディエゴ インコーポレイテッド インドール誘導体及びキナーゼ阻害剤としてのその使用
BRPI0713187A2 (pt) * 2006-07-20 2012-10-16 Mehmet Kahraman método de inibir rho-quinase, método de tratamento de doença mediada por rho-quinase, composto e composição farmacêutica
US20080242694A1 (en) * 2006-09-18 2008-10-02 D Sidocky Neil R Amino-substituted heterocycles, compositions thereof, and methods of treatment therewith
DE102007028515A1 (de) * 2007-06-21 2008-12-24 Merck Patent Gmbh 6-(Pyrrolopyridinyl)-pyrimidinyl-2-amin-derivate
CL2008001943A1 (es) 2007-07-02 2009-09-11 Boehringer Ingelheim Int Compuestos derivados de fenil-triazol, inhibidores de enzimas de señales especificas que participan del control de la proliferacion celular; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer, infecciones, enfermedades inflamatorias y autoinmunes.
EP2211620B1 (en) * 2007-10-25 2013-12-25 Merck Sharp & Dohme Corp. 3-PYRAZIN SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AS JANUS KINASE INHIBITORS FOR THE TREATMENT OF CANCER DISEASES
WO2010017047A1 (en) * 2008-08-05 2010-02-11 Merck & Co., Inc. Therapeutic compounds
DE102008038221A1 (de) * 2008-08-18 2010-02-25 Merck Patent Gmbh 7-Azaindolderivate

Also Published As

Publication number Publication date
EP2427461B1 (de) 2013-10-09
AR076750A1 (es) 2011-07-06
CA2760844C (en) 2017-09-19
EP2427461A1 (de) 2012-03-14
AU2010244772B2 (en) 2016-01-07
CN102414211A (zh) 2012-04-11
AU2010244772A1 (en) 2011-12-22
CA2760844A1 (en) 2010-11-11
DE102009019962A1 (de) 2010-11-11
CN102414211B (zh) 2014-06-04
US8541584B2 (en) 2013-09-24
KR20120014183A (ko) 2012-02-16
IL215725A (en) 2014-12-31
WO2010127754A1 (de) 2010-11-11
EA201101585A1 (ru) 2012-05-30
MX2011011488A (es) 2011-11-18
US20120053178A1 (en) 2012-03-01
SG175245A1 (en) 2011-12-29
JP5731481B2 (ja) 2015-06-10
JP2012526057A (ja) 2012-10-25
ZA201108885B (en) 2012-08-29
IL215725A0 (en) 2012-01-31
ES2436445T3 (es) 2014-01-02

Similar Documents

Publication Publication Date Title
BRPI1014459A2 (pt) derivados de 3-(1,2,3-triazol-4-il)pirrolo[2,3-b]-piridina"
BRPI0919948A2 (pt) Pirido[4,3-b]indois contendo porções rígidas
HRP20171398T1 (hr) Novi derivati adenina
BRPI0722088A2 (pt) derivados de pirrolo[2,3-b]piridina como moduladores de cinase
AP2939A (en) Thieno [2,3-B] pyridine derivatives as viral replication inhibitors
BRPI0822237A2 (pt) Compostos de imidazo [1,2-a] piridina
BRPI1006113A2 (pt) "derivado de piridina".
BRPI0908050A2 (pt) Furo-e tieno[3,2-c]piridinas
IL212285A0 (en) Azaindole derivatives
IL206276A0 (en) Pyridine derivatives
BRPI0914301A2 (pt) derivados de pirimidin-4-ona substituída
GB0702259D0 (en) 7-azaindole derivatives
IL211241A0 (en) 7-azaindole derivatives
ZA201206630B (en) Hetaryl-[1,8]naphthyridine derivatives
ZA201107350B (en) Imidazo [2 1 b] [1, 3, 4] thiadiazole derivatives
BRPI0821936A2 (pt) Derivados de 4-(pirrolo[2,3-c]piridina-3-il)pirimidin-2-ilamina
IT1393337B1 (it) Sintesi di (4as, 7as)-ottaidro-1h-pirrolo[3,4-b]piridina
BRPI0915417A2 (pt) derivados de 3-(3-pirimidin-2-il-benzil)-[1,2,4]triazolo [4,3-b]piridazina como inibidores da met quinase
PL2155712T3 (pl) 3-(imidazolilo)-pirazolo[3,4-b]pirydyny
BRPI1008173A2 (pt) "derivados de piridina espiroindolinona"
BR112012014058A2 (pt) derivados de 3,4,4a,10b- tetraidro-1h- tiopirano[4,3-c]isoquinolina
ZA201007615B (en) Aminopyridine derivatives
GB0702265D0 (en) 7-Azaindole derivatives
ZA201105257B (en) 3-(3-pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyrimidine derivatives
EP2565194A4 (en) Imidazo [1,2-A] pyridine

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]